サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536156

膿痂疹治療薬の世界市場

Impetigo Drugs

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
膿痂疹治療薬の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

膿痂疹治療薬の世界市場は2030年までに21億米ドルに達する見込み

2023年に15億米ドルと推定される膿痂疹治療薬の世界市場は、分析期間2023-2030年にCAGR 4.5%で成長し、2030年には21億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフシダンドラッグは、CAGR 5.1%を記録し、分析期間終了時には8億8,350万米ドルに達すると予測されます。キノロン系薬剤セグメントの成長率は、分析期間中CAGR 3.2%と推定されます。

米国市場は4億2,210万米ドルと推定、中国はCAGR7.5%で成長すると予測

米国の膿痂疹治療薬市場は、2023年に4億2,210万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.5%で推移し、2030年には4億3,280万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と4.7%と予測されています。欧州では、ドイツがCAGR 2.7%で成長すると予測されています。

世界の膿痂疹治療薬市場- 主要動向と促進要因まとめ

伝染性膿痂疹は、主に乳幼児が罹患する伝染性の細菌性皮膚感染症であるが、年齢に関係なく発症する可能性があります。この感染症は黄色ブドウ球菌または化膿レンサ球菌によって引き起こされ、すぐに破裂して数日間滲出し、その後黄褐色の痂皮を形成する赤いただれが特徴です。膿痂疹は通常、抗生物質で治療され、ただれに直接外用するか、重症の場合は内服します。最も一般的に処方される外用抗生物質にはムピロシンやフシジン酸があり、より広範囲の感染にはペニシリン、エリスロマイシン、セファレキシンなどの経口抗生物質が使用されます。治療法の選択は、感染症の重症度、患者の年齢、基礎疾患によって異なります。

膿痂疹治療薬の開発における最近の動向は、既存の治療に対する細菌株の有効性の向上と耐性菌の減少に重点を置いています。研究者たちは、外用抗生物質の浸透性と有効性を高めるための新しい製剤やデリバリー・システムの開発に取り組んでいます。さらに、重度の感染症や耐性感染症に対処するために、外用抗生物質と経口抗生物質の両方を利用する併用療法への関心が高まっています。分子生物学とゲノミクスの進歩により、新規抗生物質標的の同定も可能になり、耐性メカニズムを克服できる可能性のある新薬候補の開発につながっています。こうした技術革新は、抗生物質耐性菌の蔓延が増加の一途をたどり、効果的な膿痂疹の管理に重大な課題を突きつけていることから、極めて重要です。

膿痂疹治療薬市場の成長は、いくつかの要因によって牽引されています。膿痂疹の発生率は、特に温暖で湿度の高い気候と混雑した生活環境の地域で増加しており、効果的な治療に対する需要が高まっています。リポソーム製剤やナノ粒子製剤などのドラッグデリバリーシステムの技術的進歩は、薬物の安定性の向上と標的送達を提供することで対応可能な市場を拡大しています。抗生物質耐性の増加は、新しい抗生物質や併用療法の開発に拍車をかけており、これらは膿痂疹治療の有効性を維持するために極めて重要です。さらに、膿痂疹の症状や早期治療の重要性に対する保護者やヘルスケア関係者の認識が高まっていることも、市場の需要を後押ししています。また、新興市場におけるヘルスケアインフラの拡充と医療費の増加も市場成長に寄与しています。さらに、新規抗生物質の開発に対する規制当局の支援や、重要医薬品の迅速な承認プロセスが、新規治療薬の市場参入を促進しています。これらの要因が相まって、膿痂疹治療薬市場はダイナミックかつ急速に発展しています。

調査対象企業の例（全86件）

  • Grupo Ferrer Internacional, S.A.
  • GSK Plc
  • Laboratorios Ojer Pharma S.L.
  • LEO Pharma A/S
  • Lytix Biopharma AS
  • Medimetriks Pharmaceuticals, Inc.
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • UNION therapeutics A/S
  • Vaxcyte;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26854

Global Impetigo Drugs Market to Reach US$2.1 Billion by 2030

The global market for Impetigo Drugs estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Fusidane Drug, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$883.5 Million by the end of the analysis period. Growth in the Quinolones Drug segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.1 Million While China is Forecast to Grow at 7.5% CAGR

The Impetigo Drugs market in the U.S. is estimated at US$422.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$432.8 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Impetigo Drugs Market - Key Trends and Drivers Summarized

Impetigo is a highly contagious bacterial skin infection that primarily affects infants and young children, though it can occur in individuals of any age. The infection is caused by Staphylococcus aureus or Streptococcus pyogenes and is characterized by red sores that quickly rupture, ooze for a few days, and then form a yellowish-brown crust. Impetigo is typically treated with antibiotics, either topically applied directly to the sores or taken orally in more severe cases. The most commonly prescribed topical antibiotics include mupirocin and fusidic acid, while oral antibiotics such as penicillin, erythromycin, and cephalexin are used for more extensive infections. The choice of treatment depends on the severity of the infection, the patient's age, and any underlying health conditions.

Recent advancements in the development of impetigo drugs have focused on improving the efficacy and reducing the resistance of bacterial strains to existing treatments. Researchers are working on new formulations and delivery systems to enhance the penetration and effectiveness of topical antibiotics. Moreover, there is growing interest in combination therapies that utilize both topical and oral antibiotics to combat severe or resistant infections. Advances in molecular biology and genomics have also enabled the identification of novel antibiotic targets, leading to the development of new drug candidates that can potentially overcome resistance mechanisms. These innovations are critical as the prevalence of antibiotic-resistant bacteria continues to rise, posing significant challenges to effective impetigo management.

The growth in the impetigo drugs market is driven by several factors. The increasing incidence of impetigo, particularly in regions with warm, humid climates and crowded living conditions, has heightened the demand for effective treatments. Technological advancements in drug delivery systems, such as liposomal and nanoparticle formulations, have expanded the addressable market by offering improved drug stability and targeted delivery. The rise in antibiotic resistance has spurred the development of new antibiotics and combination therapies, which are crucial for maintaining the efficacy of impetigo treatments. Additionally, greater awareness of impetigo symptoms and the importance of early treatment among parents and healthcare providers is driving market demand. The expansion of healthcare infrastructure in emerging markets, along with increased healthcare spending, is also contributing to market growth. Furthermore, regulatory support for the development of new antibiotics and expedited approval processes for critical drugs are facilitating the entry of new treatments into the market. Collectively, these factors are fostering a dynamic and rapidly evolving market for impetigo drugs.

Select Competitors (Total 86 Featured) -

  • Grupo Ferrer Internacional, S.A.
  • GSK Plc
  • Laboratorios Ojer Pharma S.L.
  • LEO Pharma A/S
  • Lytix Biopharma AS
  • Medimetriks Pharmaceuticals, Inc.
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • UNION therapeutics A/S
  • Vaxcyte;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Impetigo Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Impetigo Spurs Demand for Effective Treatments
    • Technological Advancements in Drug Delivery Propel Growth
    • Development of Novel Antibiotics Expands Addressable Market Opportunity
    • Increasing Antibiotic Resistance Strengthens Business Case for New Treatments
    • Here's How Combination Therapies Generate New Market Opportunities
    • Advances in Molecular Biology and Genomics Propel Innovation in Drug Development
    • Growing Healthcare Spending in Emerging Markets Sustains Growth
    • Increasing Number of Clinical Trials Validating Efficacy and Safety of New Drugs Drive Market Confidence
    • Economic Burden of Skin Infections Strengthens Business Case for Effective Solutions
    • Here's the Story: Impact of Pediatric and Geriatric Populations on Market Demand
    • Rising Adoption of Topical Antibiotics Drives Market Growth
    • Expansion of Online Pharmacies Expands Access to Impetigo Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Impetigo Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Fusidane Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Quinolones Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sulfonamide Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tetracycline Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION